

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions of claims in the application.

**Listing of Claims**

1. – 6. (Canceled)

7. (Currently Amended) A [[The]] method for predicting pregnancy-induced hypertension according to claim 5, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject and comparing the measured value with a cut-off value that is determined from measured values of human lipocalin-type prostaglandin D synthase in body fluid samples collected from normal pregnant women not exhibiting symptoms of hypertension, proteinuria, and edema and not thought to be clinically affected with PIH and/or pregnant women with pregnancy-induced hypertension, wherein it is determined that the risk of developing PIH in the future is high when the measured value of human lipocalin-type prostaglandin D synthase is higher than the cut-off value.

8. – 10. (Canceled)

11. (Currently Amended) The method for predicting pregnancy-induced hypertension according to ~~claim 5~~ claim 7, wherein the level of human lipocalin-type prostaglandin D synthase in a body fluid sample is measured by an immunological assay method selected from the group consisting of an enzyme immunoassay method, a radio-immunoassay method, a latex agglutination assay method, and a fluorescence immunoassay method.

12. (Canceled)

13. (Currently Amended) The method according to ~~claim 4~~ claim 7, wherein the body fluid sample is blood.

14. (Currently Amended) The method according to ~~claim 4~~ claim 7, wherein the body fluid sample is urine.

15. (Canceled)

16. (New)     The method according to claim 11, wherein the body fluid sample is blood.

17. (New)     The method according to claim 11, wherein the body fluid sample is urine.